Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines.
The purpose of this study was to investigate the utility of various in vitro and in vivo methods to assess the stability of experimental vaccines containing tetanus toxoid (TT) within PLGA microspheres. In vitro, the breakdown of the encapsulating polymers into their acid components led to changes in the structure of TT, as determined by the physico-chemical methods, rendering it undetectable by capture ELISA and altering its structural integrity. The changes in TT were directly related to increasing acidity of the vaccine supernate. Purified toxoid (not encapsulated) exposed to low pH (2.5) underwent similar changes but re-neutralisation of buffer containing free toxoid, even after one week at pH 2.5 led to some re-folding of protein as determined by fluorescence spectroscopy and gel filtration chromatography. The microencapsulated vaccines were still able to generate an antibody response in mice even after prolonged pre-incubation at 37 degrees C and the apparent absence of detectable toxoid in the vaccine supernate. Electron microscopy demonstrated differences in the amount of degradation between different formulations of microspheres. Vaccines that had retained their spherical morphology after incubation in vitro for up to 28 days were able to induce protective antibodies response equal to that of freshly prepared vaccines, which indicates that the toxoid within intact microspheres remained immunogenic. Immunochemical and physico-chemical detection methods, performed on antigen released from PLGA vaccines in vitro, are valuable in providing information on product characteristics but may not be able to predict effectiveness and should be used with in vivo methods to evaluate the stability of such formulations.
Sasiak
A B
AB
Division of Bacteriology, NIBSC, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, Potters Bar, UK.
Bolgiano
B
B
Crane
D T
DT
Hockley
D J
DJ
Corbel
M J
MJ
Sesardic
D
D
D000818:Animals; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002850:Chromatography, Gel; D004337:Drug Carriers; D004355:Drug Stability; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006863:Hydrogen-Ion Concentration; D007120:Immunochemistry; D066298:In Vitro Techniques; D019344:Lactic Acid; D051379:Mice; D008855:Microscopy, Electron, Scanning; D008863:Microspheres; D009500:Neutralization Tests; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D013050:Spectrometry, Fluorescence; D013743:Tetanus Antitoxin / Q000096:biosynthesis; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000737:chemistry* / Q000276:immunology
D004337:Drug Carriers; D011108:Polymers; D013743:Tetanus Antitoxin; D013745:Tetanus Toxoid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid